KER-047 / Keros Therap - LARVOL DELTA

A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia). (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Keros Therapeutics, Inc. | N=20 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Anemia • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Myelofibrosis • Myeloproliferative Neoplasm • Oncology

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results (GlobeNewswire) - "Keros Therapeutics, Inc...today provided a business update and reported financial results for the quarter ended September 30, 2023...Following recommendation by the Safety Review Committee, dosing for Part 2 of the KER-050 Phase 2 clinical trial in patients with myelofibrosis was initiated at a starting dose of 3.75 mg/kg, with an opportunity for patients to dose escalate to 5.0 mg/kg, in both combination and monotherapy arms, and the first patient has been dosed....As part of its ongoing portfolio management activities, Keros has decided to deprioritize the KER-047 program. Accordingly, Keros is in the process of early terminating the open-label Phase 2 clinical trial of KER-047 in MDS and myelofibrosis patients with functional iron deficiency. Keros will continue to evaluate strategic partnerships and/or transactions to progress development of KER-047."

Trial status • Trial termination • Anemia • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Myelofibrosis • Myeloproliferative Neoplasm • Oncology

A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia). (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Keros Therapeutics, Inc.

New P2 trial • Anemia • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Myelofibrosis • Myeloproliferative Neoplasm • Oncology

Discovery of a novel ALK2 selective inhibitor TRND477 for the rare bone ossification condition Fibrodysplasia Ossificans Progressiva (ACS-Fall 2023) - "Herein, we describe the discovery and synthesis of a selective ALK2 inhibitor TRND477 effective in animal models of FOP. TRND477 (KER047) is currently in phase 2 clinical trials for iron-refractory iron deficiency anemia (IRIDA)."

Anemia • Hematological Disorders • ACVR1

Preliminary Results of a Phase-2 Clinical Trial of the ALK-2 Inhibitor Ker-047 for Treatment of Iron Refractory Iron Deficiency Anemia (ASH 2022) - "Data are preliminary and limited to a single participant thus far in whom KER-047 25mg q.d. was well tolerated. Changes in red cell and iron parameters at this low dose support development of KER-047 as an agent to potentially address an underlying cause of IRIDA. At the time of this abstract submission, two additional patients are scheduled for screening to complete the first dose cohort."

Clinical • P2 data • Anemia • Hematological Disorders • SMAD4 • TMPRSS6